| Published Application/Species/Sample/Dilution | Reference |
|---|
- western blot; human; loading ...; fig 5e
| Xue Z, Vis D, Bruna A, Sustic T, van Wageningen S, Batra A, et al. MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models. Cell Res. 2018;28:719-729 pubmed publisher |
- western blot; human; 1:1000; loading ...; fig 3
| Kneissl J, Hartmann A, Pfarr N, Erlmeier F, Lorber T, Keller S, et al. Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines. J Cancer Res Clin Oncol. 2017;143:573-600 pubmed publisher |
- western blot; human; loading ...; fig 10a
| Rodina A, Wang T, Yan P, Gomes E, Dunphy M, Pillarsetty N, et al. The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature. 2016;538:397-401 pubmed publisher |
- western blot; human; loading ...; fig 3a, 3b
| Buta C, Benabou E, Lequoy M, Régnault H, Wendum D, Meratbene F, et al. Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin. J Exp Clin Cancer Res. 2016;35:126 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:50; fig s1
| Koussounadis A, Langdon S, Um I, Kay C, Francis K, Harrison D, et al. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models. BMC Cancer. 2016;16:205 pubmed publisher |
- western blot; human; fig 1b
| Stindt S, Cebula P, Albrecht U, Keitel V, Schulte Am Esch J, Knoefel W, et al. Hepatitis C Virus Activates a Neuregulin-Driven Circuit to Modify Surface Expression of Growth Factor Receptors of the ErbB Family. PLoS ONE. 2016;11:e0148711 pubmed publisher |
- western blot; human; loading ...; fig s3b
| Teng Y, Pi W, Wang Y, Cowell J. WASF3 provides the conduit to facilitate invasion and metastasis in breast cancer cells through HER2/HER3 signaling. Oncogene. 2016;35:4633-40 pubmed publisher |
- western blot; human; fig 2
| Khalil H, Langdon S, Kankia I, Bown J, Deeni Y. NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies. Oxid Med Cell Longev. 2016;2016:4148791 pubmed publisher |
- western blot; human; loading ...; fig 2a
| Capparelli C, Rosenbaum S, Berger A, Aplin A. Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanoma. J Biol Chem. 2015;290:24267-77 pubmed publisher |
- western blot; human; 1:200; fig 1
| Blancafort A, Giró Perafita A, Oliveras G, Palomeras S, Turrado C, Campuzano Ã, et al. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs. PLoS ONE. 2015;10:e0131241 pubmed publisher |
- western blot; human; fig s3
| Hutchinson K, Johnson D, Johnson A, Sanchez V, Kuba M, Lu P, et al. ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. Oncotarget. 2015;6:22348-60 pubmed |
- western blot; human; loading ...; fig 4f, 4h
| Ferreira R, Law M, Jahn S, Davis B, Heldermon C, Reinhard M, et al. Novel agents that downregulate EGFR, HER2, and HER3 in parallel. Oncotarget. 2015;6:10445-59 pubmed |
- western blot; human; 1:1000; fig 1a
| Janes K. An analysis of critical factors for quantitative immunoblotting. Sci Signal. 2015;8:rs2 pubmed publisher |
- western blot; human; fig 3
| Blair B, Wu X, Zahari M, Mohseni M, Cidado J, Wong H, et al. A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations. Proteomics. 2015;15:318-26 pubmed publisher |
| Kugel C, Hartsough E, Davies M, Setiady Y, Aplin A. Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor. Cancer Res. 2014;74:4122-32 pubmed publisher |
- western blot; human; fig 2
| Brouxhon S, Kyrkanides S, Teng X, O Banion M, Clarke R, Byers S, et al. Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers. Mol Carcinog. 2014;53:893-906 pubmed publisher |
| Kitowska K, Kowalska A, Mieszkowska M, Piasecka D, Skladanowski A, Romanska H, et al. Progesterone impairs Herceptin effect on breast cancer cells. Oncol Lett. 2018;15:1817-1822 pubmed publisher |
| Takeda T, Yamamoto H, Kanzaki H, Suzawa K, Yoshioka T, Tomida S, et al. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer. PLoS ONE. 2017;12:e0171356 pubmed publisher |
| Daly C, Castanaro C, Zhang W, Zhang Q, Wei Y, Ni M, et al. FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling. Oncogene. 2017;36:471-481 pubmed publisher |
| Baumann J, Wong J, Sun Y, Conklin D. Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells. BMC Cancer. 2016;16:551 pubmed publisher |
| Deblois G, Smith H, Tam I, Gravel S, Caron M, Savage P, et al. ERR? mediates metabolic adaptations driving lapatinib resistance in breast cancer. Nat Commun. 2016;7:12156 pubmed publisher |
| Wu Y, Li R, Zhang J, Wang G, Liu B, Huang X, et al. Protein tyrosine phosphatase SHP-1 sensitizes EGFR/HER-2 positive breast cancer cells to trastuzumab through modulating phosphorylation of EGFR and HER-2. Onco Targets Ther. 2015;8:2577-87 pubmed publisher |
| Steinway S, Dang H, You H, Rountree C, Ding W. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma. PLoS ONE. 2015;10:e0128159 pubmed publisher |
| Verbeke S, Richard E, Monceau E, Schmidt X, Rousseau B, Velasco V, et al. Humanization of the mouse mammary gland by replacement of the luminal layer with genetically engineered preneoplastic human cells. Breast Cancer Res. 2014;16:504 pubmed publisher |
| Weigelt B, Lo A, Park C, Gray J, Bissell M. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat. 2010;122:35-43 pubmed publisher |
